Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 147 Carcinoma, Renal Cell 37 Parkinson Disease 4, Autosomal Dominant Lewy Body 31 Neoplasms 28 Cholangiocarcinoma 26 Endometrial Neoplasms 19 Thyroid Neoplasms 17 Liver Neoplasms 17 Melanoma 15 Stomach Neoplasms 13 Carcinoma, Non-Small-Cell Lung 13 Biliary Tract Neoplasms 13 Recurrence 9 Neoplasm Metastasis 9 Squamous Cell Carcinoma of Head and Neck 8 Ovarian Neoplasms 8 Breast Neoplasms 8 Uterine Cervical Neoplasms 7 Triple Negative Breast Neoplasms 5 Thyroid Carcinoma, Anaplastic 5 Small Cell Lung Carcinoma 5 Neuroendocrine Tumors 5 Esophageal Squamous Cell Carcinoma 5 Colorectal Neoplasms 5 Pancreatic Neoplasms 4 Kidney Neoplasms 4 Carcinoma, Transitional Cell 4 Carcinoma 4 Adenocarcinoma 4 Thyroid Cancer, Papillary 3

Interventions

vandetanib 1 pazopanib 1 olverembatinib 1 lenvatinib 1 avapritinib 1 Surgical Procedures, Operative 1 Imatinib Mesylate 1 Coal Tar 1 6-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

GIST × lenvatinib × Clear all

NCT07096609 2026-04-03

LONGIST

Asan Medical Center

Phase 1/2 Recruiting

GIST

Data powered by HemOnc (CC BY 4.0) Colophon ⚡